TNB-383B is a BCMA x CD3 T-cell engaging bispecifc antibody being
studied in relapsed or refractory multiple myeloma who have received
at least 3 prior lines of therapy.
TNB-383B is being developed by TeneoOne through Phase 1. AbbVie holds the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of TNB-383B.
Type of MoleculeBiologic
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted, Approved)|
|Multiple Myeloma (MM)||n/a||